Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 10 results.
User Information
Export Records
  1. 1.   Distinct uptake and elimination profiles for trastuzumab, human IgG and biocytin-TMR in experimental HER2+ brain metastases of breast cancer
  2. Silvestri, Vanesa L; Tran, Andy D; Chung, Monika; Chung, Natalie; Gril, Brunilde; Robinson,Christina; Difilippantonio,Simone; Wei, Debbie; Kruhlak, Michael J; Peer, Cody J; Figg, W Douglas; Khan, Imran; Steeg, Patricia S
  3. Neuro-Oncology. 2024, Feb 13;
  1. 2.   Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
  2. Zhao, Jun; Mohan, Nishant; Nussinov, Ruth; Ma, Buyong; Wu, Wen Jin
  3. Antibodies. 2021, Jan 12; 10(1):
  1. 3.   Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q
  2. Jhaveri, Komal L; Wang, Xin Victoria; Makker, Vicky; Luoh, Shiuh-Wen; Mitchell, Edith P; Zwiebel, James A; Sharon, Elad; Gray, Robert J; Li, Shuli; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams,Mickey; Hamilton, Stanley R; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Annals of oncology : official journal of the European Society for Medical Oncology. 2019, NOV; 30(11): 1821-1830.
  1. 4.   Targeting Non-coding RNA Sensitizes Cancer Cells to Drugs
  2. Yang,Mo; Schneekloth,Jay
  3. Trends in pharmacological sciences. 2019, May 20; pii: S0165-6147(19)30094-X.
  1. 5.   First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging
  2. Kurdziel, K A; Mena, E; McKinney, Y; Wong, K; Adler,Stephen; Sissung, T; Lee, J; Lipkowitz, S; Lindenberg, L; Turkbey, B; Kummar, S; Milenic, D E; Doroshow, J H; Figg, W D; Merino, M J; Paik, C H; Brechbiel, M W; Choyke, P L
  3. Journal of translational science. 2019, Apr; 5(2):
  1. 6.   Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells
  2. Moody, Terry W.; Ramos-Alvarez, Irene; Moreno, Paula; Mantey, Samuel A.; Ridnour, Lisa; Wink, David; Jensen, Robert T.
  3. PEPTIDES. 2017, Apr; 90: 90-99.
  1. 7.   HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
  2. Zielinski, R.; Lyakhov, I.; Hassan, M.; Kuban, M.; Shafer-Weaver, K.; Gandjbakhche, A.; Capala, J.
  3. Clinical Cancer Research. 2011, Aug; 17(15): 5071-5081.
  1. 8.   Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes)
  2. Smith, B.; Lyakhov, I.; Loomis, K.; Needle, D.; Baxa, U.; Yavlovich, A.; Capala, J.; Blumenthal, R.; Puri, A.
  3. Journal of Controlled Release. 2011, Jul; 153(2): 187-194.
  1. 9.   HER2-and EGFR-Specific Affiprobes: Novel Recombinant Optical Probes for Cell Imaging
  2. Lyakhov, I.; Zielinski, R.; Kuban, M.; Kramer-Marek, G.; Fisher, R.; Chertov, O.; Bindu, L.; Capala, J.
  3. Chembiochem. 2010, Feb; 11(3): 345-350.
  1. 10.   Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
  2. Maeng, Hoyoung M; Moore, Brittni N; Bagheri, Hadi; Steinberg, Seth M; Inglefield,Jon; Dunham,Kim; Wei, Wei-Zen; Morris, John C; Terabe, Masaki; England, Lee C; Roberson, Brenda; Rosing, Douglas; Sachdev, Vandana; Pack, Svetlana D; Miettinen, Markku M; Barr, Frederic G; Weiner, Louis M; Panch, Sandhya; Stroncek, David F; Wood, Lauren V; Berzofsky, Jay A
  3. Frontiers in Oncology. 2021 11: 789078.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel